|   LifeSciVC

The Promise Of Precision Neuroscience And Launch Of Arkuda Therapeutics

By Bruce Booth, DPhil, Partner

Neuroscience has had a tough run of news lately. With Amgen deprioritizing neuro this year, Pfizer doing the same last year, and others like BMS, GSK, and AZ cutting back on CNS a few years earlier, it would seem dark times for neuroscience R&D. Add to that the recent unpredictable complexity around Biogen’s aducanumab, where hugely expensive Phase 3 trials are caught in the maelstrom between negative futility and positive analysis, and it might further question why anyone would want to work in the space.

Read more.